Identification | Back Directory | [Name]
4-[3-(Methylsulfonyl)phenyl]-1-propylpiperidine | [CAS]
346688-38-8 | [Synonyms]
ACR 16 ASP 2314 FR 310826 Pridopidine Acr16 compound 4-(3-Methylsulfonylphenyl)-1-propylpiperidine 4-[3-(Methylsulfonyl)phenyl]-1-propylpiperidine 4-(3-Methanesulfonyl-phenyl)-1-propyl-piperidine Piperidine, 4-(3-(methylsulfonyl)phenyl)-1-propyl- | [Molecular Formula]
C15H23NO2S | [MDL Number]
MFCD09835586 | [MOL File]
346688-38-8.mol | [Molecular Weight]
281.42 |
Chemical Properties | Back Directory | [Appearance]
Off-White Solid | [Melting point ]
73-750C | [Boiling point ]
434.2±45.0 °C(Predicted) | [density ]
1.092±0.06 g/cm3(Predicted) | [storage temp. ]
Refrigerator, Under Inert Atmosphere | [solubility ]
Soluble in DMSO (up to 10 mg/ml). | [form ]
solid | [pka]
9.09±0.10(Predicted) | [color ]
White | [Stability:]
Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 3 months. |
Hazard Information | Back Directory | [Chemical Properties]
Off-White Solid | [Uses]
A new modulator of dopamine neurotransmission. Dopamine is a neurotransmitter in the brain. Drugs that act at central dopamine receptors are commonly used in the treatment of neurologic and psychiatric disorders. | [Description]
Pridopidine (346688-38-8) is being studied as a potential treatment for Huntington’s disease, Parkinson’s disease, and schizophrenia based on its locomotor stabilizing and antipsychotic-like effects.1,2?It was, unusually, able to reverse both hypo- and hyperdopaminergia depending on local dopamine concentrations without inducing catalepsy. This was originally attributed to functional dopamine D2 antagonism with fast on/off kinetics (“dopamine stabilizer”).3?More recent studies have attributed pridopidine’s effects to its being a more potent sigma-1 ligand than a D2 ligand.4,5?Displays neuroprotective/restorative effects6,7?and ameliorates central features of amyotrophic lateral sclerosis pathology8?in a sigma-1-mediated manner | [in vivo]
Pridopidine is known to act as a low affinity D2R antagonist. Pridopidine’s activity may be attributed to binding the sigma 1 receptor (S1R), an endoplasmic reticulum (ER). To strengthen the hypothesis that the BDNF pathway is upregulated due to activation of the S1R, SD rats are treated with lower doses of Pridopidine (range 0.3-60 mg/kg), and analysed the expression of seven selected genes in the BDNF pathway by qPCR. Pridopidine doses of 3 and 15 mg/kg in rats occupy 57±2% and 85±2% of S1R, respectively, and both do not show occupancy of the D2R, as determined by in vivo PET imaging. The significant occupancy proportion of the D2R (44-66%) is observed only at a dose of 60 mg/kg. This PET study supports the conclusion that the upregulation of genes in rats treated with 15 mg/kg Pridopidine are a result of specific activation of the S1R. At 30 mg/kg, partial/low occupancy of the D2R is at levels of 22-33% (assuming linearity), and S1R is saturated. Indeed, qPCR analysis reveals that the upregulation of EGR1 (already up at 3 mg/kg), EGR2, HOMER1A, KLF5, and ARC expression are upregulated at the low 15 mg/kg dose and expression of CDNK1A and CEBPB are significantly upregulated from a low dose of 30 mg/kg (CEBPB is significantly increased at 3 mg/kg but not at 15 mg/kg)[1]. To further confirm the beneficial effect of Pridopidine on HD motor phenotype and to elucidate whether Pridopidine may act also as neuroprotective agent, preclinical studies in R6/2 mice have been undertaken. Daily administration of Pridopidine at a dose of 5 mg/kg, the most effective dose with no adverse effects, starting at the pre-symptomatic stage at 5 weeks for 6 weeks, significantly preserves motor function and prevents the progressive and dramatic motor worsening commonly observed in R6/2 mice. The beneficial effects of Pridopidine are maintained for about 4 weeks, after which mice show a slight worsening in performing both the horizontal ladder task and the open field. In addition, according to a Kaplan-Meier survival curve analysis, Pridopidine efficiently extends lifespan in the same mice[2]. | [IC 50]
D2 Receptor | [storage]
Store at -20°C | [References]
1) Pettersson (2010),?Synthesis and Evaluation of a Set of 4-Phenylpiperidines and 4-Phenylpiperazines as D2 Receptor Ligands and the Discovery of the Dopaminergic Stabilizer 4-[3-(Methylsulfonyl)phenyl]-1-propylpiperidine (Huntexil, Pridopidine, ACR16);?J.Med.Chem.?53?2510
2)?The dopamine stabilizers (S)-(-)-(3-methanesulfonylphenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonylphenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for motor side effects in the rat;?J.Pharmacol.Exp.Ther.?318?810
3) Dyhring?et al.?(2010)?The dopaminergic stabilizers pridopidine (ACR16) and (-)-OSU6162 display dopamine D(2) receptor antagonism and fast receptor dissociation properties;?Eur.J.Pharmacol.?628?19
4) Sahlholm (2015)?Pridopidine selectively occupies sigma-1 rather than dopamine D2 receptors at behaviorally active doses;?Psychopharmacology (Berl)?232?3443
5)?Sahlholm?et al.?(2013),?The dopamine stabilizers ACR16 and (-)-OSU6162 display nanomolar affinities at the?s-1 receptor;?Mol.Psychiatry?18?12
6) Francardo?et al.?(2019),?Pridopidine Induces Functional Neurorestoration Via the Sigma-1 Receptor in a Mouse Model of Parkinson’s Disease;?Neurotherapeutics?16?465
7) Ryskamp,?et al.?(2017),?The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease;?Neurobiol.Dis.?97(Pt A)?46
8) Ionescu?et al.?(2019),?Targeting the Sigma-1 Receptor via Pridopidine Ameliorates Central Features of ALS Pathology in a SOD1G93A Model;?Cell Death Dis.?10?210 |
|
Company Name: |
Cool Pharm, Ltd
|
Tel: |
021-58581007 18019463053 |
Website: |
http://www.coolpharm.com |
Company Name: |
TaiChem Taizhou Limited
|
Tel: |
052386810091 |
Website: |
https://www.chemicalbook.com/supplier/11410902/1.htm |
|